Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

The Affiliated Hospital of Southwest Medical University | China

Author Profile:

Scopus

👨‍⚕️ MR. FENGXU YU – PIONEER IN CARDIOVASCULAR INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Born in January 1976, Professor Fengxu Yu embarked on his medical journey with a strong academic foundation, earning his M.D. and later achieving qualifications as a doctoral supervisor. His passion for cardiovascular science led him to pursue postdoctoral training in France, equipping him with a global perspective and refined clinical research skills. This international exposure laid the groundwork for his future leadership in complex cardiovascular research and surgical practice.

💼 PROFESSIONAL ENDEAVORS

Currently serving as a Professor at The Affiliated Hospital of Southwest Medical University, Dr. Yu holds several distinguished roles:

  • Standing Committee Member, Cardiac Surgery Committee (CAMEA)

  • Committee Member, Heart Valve Committee (CRHA)

  • Vice Chair, Sichuan Thoracic & Cardiac Surgery Association

  • Academic Leader, recognized by the Sichuan Health Commission

  • Member, Asian Heart Valve Society, China Chapter

  • Recipient, Luzhou Top Talent Award

His consistent dedication has cemented his role as a leading figure in thoracic and cardiac surgery across China.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ATRIAL FIBRILLATION

Dr. Yu’s research endeavors focus on molecular and biomechanical mechanisms in cardiovascular disease, especially atrial fibrillation (AF), atherosclerosis, and aortic dissection. His current areas of exploration include:

  • Non-coding RNAs (e.g., circRNA/ceRNA networks) in AF pathogenesis

  • Application of induced pluripotent stem cells in modeling AF

  • Effects of shear stress on vascular endothelial health and its link to atherosclerosis

Through these efforts, Dr. Yu bridges basic science with clinical relevance, advancing the future of personalized medicine.

📊 IMPACT AND INFLUENCE

As a principal investigator, Dr. Yu has led nearly 20 major research projects funded by provincial and municipal institutions. He has also contributed to 30+ collaborative studies as a lead or co-investigator. His academic output includes over 50 peer-reviewed publications, with 12 articles indexed in SCI journals and 20+ papers in national core journals, showcasing his thought leadership in cardiovascular science.

📚 SELECTED RESEARCH PROJECTS

Some of Dr. Yu’s notable funded projects include:

  • Mechanism of Shear Stress-Downregulated Annexin A1 (2019)

  • circRNA-Regulated ceRNA Networks in AF (2025)

  • Personalized Warfarin Therapy Post-Valve Replacement (2022)

  • Hsa_circ_0025573—miR-133b—MMP9 in AF Pathogenesis (2022)

  • SRB1-Mediated Endothelial Injury in Atherosclerosis (2018)

These projects reflect a multidisciplinary approach to understanding and treating cardiovascular conditions.

🏅 ACADEMIC CITES AND MEMBERSHIPS

Professor Yu actively contributes to national and international academic bodies. His memberships include:

  • CAMEA – Cardiac Surgery Committee

  • CRHA – Heart Valve Committee

  • Sichuan Thoracic & Cardiac Surgery Association

  • Asian Heart Valve Society – China Chapter

These affiliations enhance his visibility in shaping future cardiac surgery standards and innovations.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Professor Fengxu Yu is a mentor, innovator, and academic leader. His mentorship of graduate students, collaboration with international institutions such as Heidelberg University, and continued work on translational research ensure a legacy of impactful science. As cardiovascular disease remains a global challenge, his pioneering work in non-coding RNA and biomechanical interactions is poised to redefine prevention and treatment strategies.

📑 NOTABLE PUBLICATIONS

"Myocardial infarction serum preconditioning bone marrow mesenchymal stem cell-derived exosomes enhance anti-fibrosis in rat myocardial infarction hearts" 

Authors: Y., Gan, Yang , C., Wang, Changyi , R., Liao, Ruili , ... H., Liu, Hui , Y., Fu, Yong
Journal: Molecular and Cellular Biochemistry.
Year: 2025

"Identification of the optimal reference genes for atrial fibrillation model established by iPSC-derived atrial myocytes" 

Authors: L., Li, Lei , Z., Zhao, Zijuan , Z., Liu, Zihao , ... Y., Nie, Yongmei , F., Yu, Fengxu
Journal: BMC Genomics
Year: 2024

"Postoperative delirium prediction after cardiac surgery using machine learning models" 

Authors: T., Yang, Tan , H., Yang, Hai , Y., Liu, Yan , ... Y., Zhang, Ying , F., Yu, Fengxu
Journal: Computers in Biology and Medicine
Year: 2024

Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

🏛️ PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Ma’s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

  • Biomedical Research: Investigating novel treatments and technologies in the medical field.
  • Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
  • Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

🌍 IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

📖 ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

  • Advances in medical treatments and techniques.
  • Healthcare policy improvements.
  • Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Ma’s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

  • Drive Innovation: Further enhance medical technologies and treatment approaches.
  • Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
  • Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

🔥 CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

α-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024